Angiogenesis Inhibitors and Hypertension: Clinical Aspects

Completed

• Conditions: high blood pressure; hypertension; 10057166

• Registration Number: NL-OMON31245
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Men and women, with either renal cell carcinoma or gastrointestinal stromal tumors (GIST) intended to be treated solely with Sunitinib (single-agent treatment) and who are considered fit enough by their treating physician to receive Sunitinib.

Exclusion Criteria

None

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified